XTX Topco Ltd Has $506,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

XTX Topco Ltd lessened its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 58.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,092 shares of the company’s stock after selling 38,976 shares during the quarter. XTX Topco Ltd’s holdings in Teva Pharmaceutical Industries were worth $506,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TEVA. Sequoia Financial Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after acquiring an additional 805 shares in the last quarter. Smithfield Trust Co increased its stake in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Signaturefd LLC raised its holdings in Teva Pharmaceutical Industries by 16.9% during the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after buying an additional 1,094 shares during the period. Bridgewater Associates LP boosted its holdings in shares of Teva Pharmaceutical Industries by 5.2% in the third quarter. Bridgewater Associates LP now owns 23,222 shares of the company’s stock valued at $418,000 after buying an additional 1,144 shares during the period. Finally, United Services Automobile Association increased its position in shares of Teva Pharmaceutical Industries by 3.1% during the second quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock worth $669,000 after acquiring an additional 1,249 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Down 1.8 %

NYSE:TEVA opened at $16.50 on Friday. The firm has a market capitalization of $18.69 billion, a price-to-earnings ratio of -19.41, a price-to-earnings-growth ratio of 1.04 and a beta of 0.79. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a twelve month low of $9.90 and a twelve month high of $19.31. The stock’s 50 day moving average price is $17.51 and its two-hundred day moving average price is $17.39.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of several research reports. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group lifted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.